In a filing, Calidi Biotherapeutics Inc revealed its CEO and Chairman of the Board Camaisa Allan unloaded Company’s shares for reported $16200.0 on Dec 17 ’24. In the deal valued at $1.62 per share,10,000 shares were sold. As a result of this transaction, Camaisa Allan now holds 66,712 shares worth roughly $56705.2.
H.C. Wainwright initiated its Calidi Biotherapeutics Inc [CLDI] rating to a Buy in a research note published on November 22, 2023; the price target was $11. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early October with a ‘”an Outperform”‘ rating.
Price Performance Review of CLDI
On Tuesday, Calidi Biotherapeutics Inc [AMEX:CLDI] saw its stock fall -12.33% to $0.85. Over the last five days, the stock has lost -34.01%. Calidi Biotherapeutics Inc shares have fallen nearly -25.97% since the year began. Nevertheless, the stocks have fallen -91.41% over the past one year. While a 52-week high of $16.80 was reached on 02/12/25, a 52-week low of $0.58 was recorded on 01/30/25. SMA at 50 days reached $1.1929, while 200 days put it at $1.5518.
Levels Of Support And Resistance For CLDI Stock
The 24-hour chart illustrates a support level at 0.7709, which if violated will result in even more drops to 0.6905. On the upside, there is a resistance level at 0.9608. A further resistance level may holdings at 1.0703. The Relative Strength Index (RSI) on the 14-day chart is 39.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.2942, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.07%. Stochastics %K at 17.40% indicates the stock is a buying.
